Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugate
27/6/2022
0:00
11:24
Patients with metastatic breast cancer whose tumors express low levels of HER2 are generally classified and treated as having HER2-negative disease. However, Dr. Shanu Modi of the Memorial Sloan Kettering Cancer Center and a group of international collaborators explored the use of a monoclonal antibody–drug conjugate (trastuzumab–deruxtecan) in patients with disease they classify as HER2-“low.” Compared […]
The post Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugate first appeared on Clinical Conversations.Altri episodi di "Clinical Conversations"
Non perdere nemmeno un episodio di “Clinical Conversations”. Iscriviti all'app gratuita GetPodcast.